China Lanreotide Peptide Powder (INN) for Neuroendocrine Tumors
  • Vote Up0Vote Down venynxvenynx
    Posts: 2,986Member
    China Lanreotide Peptide Powder (INN) for Neuroendocrine Tumors





    Lanreotide powder
    (INN) is a medication used in the management of acromegaly and symptoms
    caused by neuroendocrine tumors, most notably carcinoid syndrome.

    Lanreotide is used in the treatment of acromegaly, due to both pituitary
    and non-pituitary growth hormone-secreting tumors, and the management
    of symptoms caused by neuroendocrine tumors, particularly carcinoid
    tumors and VIPomas. In the United States and Canada, lanreotide is only
    indicated for the treatment of acromegaly. In the United Kingdom, it is
    also indicated in the treatment of thyrotrophic adenoma,a rare tumor of
    the pituitary gland which secretes TSH.



    Lanreotide also shows activity against non-endocrine tumors, and, along
    with other somatostatin analogues, is being studied as a possible
    general antitumor agent.



    Synonyms:LANREOTIDE;AUTOGEL;BETA-(2-NAPHTHYL)-D-ALA-CYS-TYR-D-TRP-LYS-VAL-CYS-THR

    AMIDE;BIM-23014;ANGIOPEPTIN;H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2;H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2,
    (DISULFIDE BOND);IPSTYL

    CAS:108736-35-2

    MF:C54H69N11O10S2

    MW:1096.32

    Product Categories:hormones

    storage temp. :20°C

    Chemical Properties:White to off-white lyophilised powder

    Lanreotide Introduction:

    Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and
    marketed under the trade name Somatuline. It is available in several
    countries, including the United Kingdom, Australia and Canada, and was
    approved for sale in the United States by the Food and Drug
    Administration (FDA) on August 30, 2007.

    Lanreotide Indications

    Lanreotide is used in the treatment of acromegaly, due to both pituitary
    and non-pituitary growth hormone-secreting tumors, and the management
    of symptoms caused by neuroendocrine tumors, particularly carcinoid
    tumors and VIPomas. In the United States and Canada, lanreotide is only
    indicated for the treatment of acromegaly. In the United Kingdom, it is
    also indicated in the treatment of thyrotrophic adenoma, a rare tumor
    of the pituitary gland which secretes.



    Lanreotide also shows activity against non-endocrine tumors, and, along
    with other somatostatin analogues, is being studied as a possible
    general antitumor agent.



    Lanreotide ,In Dec 2014 the US FDA approved lanreotide for the treatment
    of patients with unresectable, well or moderately differentiated,
    locally advanced or metastatic gastroenteropancreatic neuroendocrine
    tumors (GEP-NETs).

Howdy, Stranger!

It looks like you're new here. If you want to get involved, click one of these buttons!

Top Posters

Who's Online (0)